Farming Flexibility Act of 2013

The FIRE Cancer Act of 2025, despite its misleading original title, directly amends the Federal Fire Prevention and Control Act of 1974. It establishes cancer prevention programs for firefighting personnel, explicitly including multi-cancer early detection testing. The bill authorizes $700,000,000 for these grants under subsection (c)(3)(F), with a maximum of $1,750 per multi-cancer early detection test. This represents a new, substantial funding allocation for a specific type of medical service, creating a direct market opportunity for diagnostic companies. The money trail is clear: $700 million is authorized for grants under the Assistance to Firefighters Grant program, specifically for cancer prevention programs and early detection tests. Fire departments and emergency medical services organizations will apply for these grants, which will then be used to procure multi-cancer early detection tests. Companies providing these tests are direct beneficiaries. Additionally, the bill establishes a joint cancer research program between FEMA and the CDC, where anonymized test results will be shared, which could further drive demand for specific testing methodologies or lead to new research and development opportunities for diagnostic firms. Historically, government initiatives to fund specific medical screenings or treatments have driven significant revenue for the targeted industries. For example, when the Affordable Care Act expanded coverage for preventative services in 2010, diagnostic and screening companies saw increased utilization. While not a direct parallel, the establishment of a dedicated $700 million fund for a specific type of test creates a guaranteed demand floor. The bill was introduced on February 26, 2025, and referred to the Committee on Science, Space, and Technology. The next step is committee consideration and potential markup. Specific winners include companies offering multi-cancer early detection tests. Guardant Health ($GH) offers the Shield multi-cancer early detection test. Exact Sciences ($EXAS) is known for its Cologuard test and is developing other early detection technologies. Illumina ($ILMN), a leader in genomic sequencing, provides foundational technology for many early detection tests. Laboratory Corporation of America Holdings ($LH) and Quest Diagnostics ($DGX), as major diagnostic service providers, are well-positioned to process these tests and benefit from increased volume. Losers are not directly identifiable, as this bill creates new spending rather than restricting existing markets. Following committee referral, the bill will undergo hearings and potential amendments. If it passes committee, it moves to a floor vote in the House. Should it pass the House, it proceeds to the Senate for a similar process. The $700 million authorization becomes available upon enactment, driving immediate demand for the specified tests.